INTRODUCTION
Diabetes mellitus (DM) is a critical public health issue globally and its prevalence is increasing mostly in developing countries. [1] [2] [3] [4] The number of diabetics between 20 and 79 years of age is estimated to be 415 million people in the world and is expected to rise to 642 million in 2040. [5] Iran is one of the most populous countries of the Middle East and the prevalence of diabetes in Iran ranges from 7.7% to 14% in the population aged over 20 years. [2, 6, 7] In addition, it is estimated that Iran would take the second place in diabetes annual growth after Pakistan. [2] Diabetic retinopathy (DR) is one of the major complications of diabetes and leading cause of visual impairment or blindness. [8] [9] [10] [11] [12] [13] [14] [15] [16] Evidence reveals that nearly all type I and 60% of type II diabetic patients develop some degrees of retinopathy 20 years after diagnosis. [17] Given the increasing number of diabetics worldwide, it is expected that the prevalence of DR increases especially in developing countries. [14] Similarly, DR is a major cause of visual impairment and loss in Iran. [10, 11, 18, 19] Based on the current data, 37% and 29.6% of diabetic cases have some degrees of DR in Tehran and Yazd provinces, respectively. [11, 19] On the other hand, therapeutic interventions can prevent the development of severe visual impairment caused by DR in up to 90% of cases. [20] National clinical practice guidelines (CPGs) comprise thorough clinical recommendations based on valid evidence and are adapted considering their safety, efficacy, cost of diagnostic or therapeutic interventions, and the nation's needs. These guidelines increase the efficacy of interventions and provide equity in access to treatment for all members of the society. Since CPGs focus on a particular problem, for instance one disease, they can help both the physicians and the patients in making an appropriate decision. These instructions can also be effective in guiding health care policy makers at a national scale. Therefore, clinical guidelines increase both accessibility and quality of health care services. [21, 22] Paragraph D, article 32 of the Fifth 5-Year Development Plan of Iran and the Strategic Objective No. 75 of the Iranian Ministry of Health and Medical Education emphasize on the development, adaptation and implementation of clinical practice guidelines, and extension of health care services and development of evidence based health care at a national level. [23, 24] Considering the growing prevalence of diabetes and DR in Iran, its impact on public health, costs imposed on the health care system, and in order to establish the objectives of the 
Screening the Guidelines
The extracted guidelines were screened using the AGREE (appraisal of guidelines for research and evaluation) tool.
[25] Ultimately, 3 DR guidelines by the Royal College of Ophthalmologists (2013), [26] American Academy of Ophthalmology (Preferred Practice Pattern 2012), [20] and Australian Diabetes Society (2008) [27] were selected as the reference CPGs.
M e t h o d s U s e d f o r C u s t o m i z i n g Recommendations

Evaluating and appraising the reference CPGs' recommendations
Initially, 20 questions on DR were designed and the questions' components (PICO; Patient, Intervention, Comparison, Outcome) were entered in Table 1 . Subsequently, the answers to the questions were extracted from the reference CPGs and the responses were recorded in the same table.
In the process of extraction and analysis of the responses, the questions were evaluated once again and broken down into smaller questions if necessary, and all the above-mentioned steps were repeated for each.
Analyzing the supporting evidence
The details of each evidence were recorded in Table 2 . Tables 3 shows the levels of evidence.
Evaluating the recommendations in terms of clinical benefits and adaptability
After completing Tables 1 and 2 , the customization team composed the clinical recommendations respecting the clinical benefits including cost, benefits, and side effects and then recorded those in Table 4 . Consequently, the recommendations were revised in Table 5 according to three customization criteria: 1-applicability (access to proper equipments, skills at using them, and their affordability for patient), 2-acceptability (patient's preferences, cultural considerations and patient's acceptability of the therapeutic protocol), 3-compatibility (similarity between patient's characteristics/disease type and their interference with studied evidence).
Consensus
All recommendations together with complementary instructions and Tables 1, 2, 4 and 5 were sent to the chairs of the retina and vitreous departments at Ahvaz Jundishapur, Gilan, Iran, Isfahan, Mashad, Tabriz, Tehran, Shahid Beheshti, Shahid Sadoughi, Shiraz and Zahedan Universities of Medical Sciences. As the experts in the field of DR, they were asked to score each recommendation in terms of clinical benefits and customizability, and to provide a total score for each recommendation at the end. In addition, they were asked to provide any further evidence that could potentially change the recommendation.
Analyzing the consensus scores and developing the final recommendations
Experts scored the recommendations based on the RAM model.
[28] The scores were analyzed and the agreement level for each recommendation was identified. The agreed recommendations were considered as the final Table 1 . Analysis of recommendations
Question P I (E) C O Type of question
Referenced guidelines
Phrase of recommendation
Level of evidence
Inconsistency of recommendations
Technical breakthrough
New systematic review New Studies
G1 G2 G3
P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; G1, American Academy of Ophthalmology (2012); G2, Royal College of England (2013); G3, Australian Diabetes Association (2008) recommendations. The experts discussed the non-agreed ones in a session and after applying the required changes, the final recommendations were developed.
All customized recommendations are presented in the results section of this article along with their reference numbers and their evidence levels (EL).
RESULTS
Recommendations for Screening, Risk Factors and Follow-up
Screening and examination
As reported by the screening programs in the US, England, and Australia, the modality of choice to screen for DR is retinal digital imaging with mydriasis which has a sensitivity of 73-96% and specificity of 78-99%. Considering its feasibility, this test is recommended for screening of DR in Iran as well. [29] [30] [31] [32] [33] [34] [35] [36] (EL: I)
Considering the few reported side effects of tropicamide eye drop 1% (1 to 6 in 20,000 cases in different studies) and to improve the sensitivity of funduscopy, it can be used to provide mydriasis for DR screening in diabetic patients except in those with history of glaucoma. [37] [38] [39] [40] [41] [42] [43] [44] (EL: I)
Risk factors
Duration of diabetes
Regardless of the type, those with longer disease duration are at greater risk for development and progression of DR. Therefore:
• Funduscopy is strongly recommended for type II diabetics at their first eye examination.
• It is recommended that type I diabetics undergo funduscopy 3 to 5 years after diagnosis of diabetes. [17, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] (EL: II) If patients are found to have signs of retinopathy, a follow-up plan should be set up based on the severity of the retinopathy.
(EL: Consensus -IV)
Blood sugar
Although tight glycemic control does not necessarily prevent the development of DR, it is recommended that diabetic patients control blood glucose and HbA1C levels in order to reduce the risk of DR progression and consequently the need for treatment. [45, [55] [56] [57] [58] [59] [60] (EL: I)
Blood pressure
Target systolic blood pressure of less than 130 mmHg is recommended for diabetic patients to slow down the progression of DR. [61] [62] [63] [64] [65] (EL: I)
Serum lipids
• Elevated serum lipid levels increase the risk of development and progression of DR. Therefore, control of serum lipids with statins and fibrates is recommended in diabetic patients. [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] (EL: I) • Hyperlipidemia has been identified as a risk factor for exudative diabetic macular edema. Therefore, control of serum lipids is recommended as a preliminary therapeutic measure in diabetic patients. [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] (EL: II) 
Kidney disorders
• It is recommended that the patients with diabetes and coexisting kidney disease undergo careful retinal examination due to the risk of developing DR (up to 58%) [82] • It is recommended that the patients with advanced DR undergo thorough renal function evaluation due to the risk of developing kidney disorders (about 15%). [82] (EL: II)
Vitamin D
As vitamin D deficiency can be associated with progression of DR, consultation with a specialist (endocrinologist, gastroenterologist, or nephrologist) is warranted for diabetic patients with vitamin D deficiency and coexisting renal and gastrointestinal problems. [83] [84] [85] (EL: II)
Smoking
Cigarette smoking has been associated with lower incidence of DR, however, considering the higher rate of morbidity and mortality among smokers, smoking cessation is recommended. [64, 77, [86] [87] [88] [89] [90] [91] [92] [93] [94] (EL: II)
Pregnancy
A two-fold increase in the risk of DR development during pregnancy warrants educating diabetic women planning a pregnancy. In addition, they should be monitored by regular blood glucose checks and retinal examination during and after the course of pregnancy. [95] [96] [97] [98] [99] [100] [101] [102] planning a pregnancy. [95] [96] [97] [98] [99] [100] [101] [102] (EL: I)
Genetics
It appears that certain genes are involved in the development and progression of DR that could vary by ethnicity and geographical origin. [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] (EL: II) Therefore, it is recommended that patients with positive family history of DR undergo more frequent eye examinations. (EL: Consensus -IV)
Coexisting eye diseases with diabetes
• Other diabetic eye diseases such as cataract, optic neuropathy, extraocular muscle paralysis, rubeosis iridis, and the delay in corneal epithelium healing should be taken into consideration in patients with DR. [123] [124] [125] [126] • It is recommended to examine the iris and angle for the presence of neovascularization prior to initialization of mydriatic eye drops. [123] [124] [125] [126] • Diabetic candidates for keratorefractive surgery should be well informed about the delayed corneal epithelium wound healing prior to surgery. [123] [124] [125] [126] (EL: II, Consensus -IV)
Referral and follow-up approach in patients with diabetes
It is recommended to examine the patients with R2 level DR (preproliferative) according to the National Screening Committee Severity Classification System or level 43 (moderate NPDR) according to the Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Classification System at 4-month intervals.
[37, 63, [127] [128] [129] [130] [131] Diabetic patients should be referred to and followed by ophthalmologists according to the following protocol: [37, 63, [127] [128] [129] [130] [131] • All type 2 diabetic patients should undergo fundus examination (with pupil dilatation) and visual acuity measurements at the time of diagnosis and at least every 2 years thereafter. 
Recommendations for Diagnosis
Retinal imaging Indications for fluorescein angiography
It is recommended that patients with DR undergo fluorescein angiography in the following conditions: [132] [133] [134] [135] • In cases where funduscopic findings cannot justify the visual impairment (to rule out macular ischemia [97, [136] [137] [138] [139] [140] [141] [142] [143] • In patients with prior hand, axillary or breast lymph node dissection, dye injection in the ipsilateral side is contraindicated. [97, [136] [137] [138] [139] [140] [141] [142] [143] (EL: Consensus -IV)
Different types of fluorescein angiography
Wide-field fluorescein angiography is superior in cases with peripheral retinal lesions as it could alter the classification of the DR and therapeutic and follow-up approaches.
(EL: II) Availability of wide-field fluorescein angiography can be limited to the major ophthalmology centers. [144, 145] (EL: Consensus -IV)
Other imaging modalities
New imaging modalities for evaluation of DR include optical coherence tomography (OCT), retinal thickness analysis (RTA) techniques, and fundus autofluorescence (FAF). • Due to the particular properties of OCT such as demonstrating different layers of retina, the use of OCT is recommended in the following conditions: o To determine the macular thickness in diabetic macular edema (before and after treatment) o To detect vitreoretinal traction or any membrane on the macula • Due to the particular properties of new fluorescein angiography techniques (SLO [Scanning Laser Ophthalmoscopy] Angiography) such as high-speed imaging, high resolution, possibility of digitally storing the images, and integrating the patients' data from different medical centers, it is suggested these imaging modalities be available in the majority of public and private settings.
• FAF can investigate functional changes in retinal pigment epithelium (RPE) without the injection.
(EL: III)
Classification of DR and diabetic macular edema
The most appropriate classification system (severity grading) of DR and diabetic macular edema (DME) could be selected based on the level of health care service offered. Due to the lower complexity, the lower-level health care provider can utilize the International Clinical 
Indications of macular laser treatment
Macular laser photocoagulation should be considered in the following conditions: [135, 191, [215] [216] [217] [218] • Presence of clinically significant macular edema (CSME) Follow-up after macular laser photocoagulation
• According to DRS and ETDRS, patients should be followed at 2-4 month intervals after macular laser treatment; decision for retreatment will be based upon visual acuity (20/30 or 20/40) and involvement of the central macula thereafter. [135, 215, 216] (EL: I)
New laser therapy techniques
New laser treatment techniques can minimize the damage to the internal retinal layers and include the followings: [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] • Minimally invasive subthreshold laser • Pattern automated scanner laser (PASCAL) (EL: I) Recommendation: Considering the lower risk of retinal damage with minimally invasive subthreshold technique, a limited number of laser machines equipped with these technologies are recommended to be available in ophthalmology centers. [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] (EL: IV -Consensus)
Intravitreal injection Indications
Intravitreal injection of anti-VEGF drugs is recommended in the following conditions: [169, • Diabetic patients with diffuse macular edema and poor prognosis for focal laser treatment • Patients with PDR or florid PDR and no response to laser therapy • Patients with neovascularization of iris (NVI) and neovascular glaucoma (NVG) • For patients with concomitant DR and cataract, consultation with a retinal specialist may be considered prior to cataract surgery whether intravitreal injection should be carried out at the time of cataract surgery (EL: I)
Intravitreal injection before vitrectomy
• Patients with PDR and active neovascularization who have been planned for vitrectomy may receive intravitreal anti-VEGF injection within one week before surgery to minimize intraoperative and early postoperative bleeding. [327] (EL: I) • Patients with advanced DR and active fibrovascular tissue who are vitrectomy candidates may receive intravitreal anti-VEGF injection within one week before the surgery to minimize the risk of bleeding during and after the surgical procedure. [328] [329] [330] [331] [332] (EL: I) • Extensive fibrovascular tissue increases the risk of traction retinal detachment following intravitreal injection of anti-VEGF drugs; the time interval between the injection and vitrectomy should be not more than 2-3 days in such cases. [328] [329] [330] [331] [332] [333] [334] (EL: II)
Intravitreal agents
None of the intravitreal anti-VEGF agents is preferred over the others and the treatment choice depends on the availability and cost. [215, 240, 244, 247, 284, 302, 303, 315, 316, 318, 321, [332] [333] (EL: Consensus -IV)
Complications
Complications of intravitreal injection treatment:
• Specific potential complications: o Anti-VEGF drugs: Thromboembolic events, blood pressure elevation, myocardial infarction (MI) and stroke. Recommendation: Patients with the past history of MI, stroke, thromboembolism, or uncontrolled hypertension, should receive intravitreal anti-VEGF injection after consultation with a cardiologist. [238, 239, 307, 333, 335, 336] (EL: I) Recommendation: Intravitreal triamcinolone injection is not recommended for phakic eyes with the past history of glaucoma. [238, 239, 307, 333, [335] [336] [337] (EL: I) • General complications:
Endophthalmitis, retinal detachment, lens damage and cataract, vitreous hemorrhage, subconjunctival hemorrhage and pain.
Recommendation: Intravitreal injection should be carried out under aseptic conditions to prevent endophthalmitis. In addition, the anatomy of the eye should be kept in mind to minimize the risk of damage to ocular tissues. [238, 239, 307, 333, [335] [336] [337] (EL: IV)
Recommendation: Intravitreal anti-VEGF injection is not recommended in eyes with advanced PDR and significant fibrous proliferation due to the risk of traction retinal detachment except in vitrectomy candidates. [238, 239, 307, 333, [335] [336] [337] (EL: II)
Vitrectomy Indications
Vitrectomy is recommended for diabetic eyes in the following conditions: [157, [338] [339] [340] [341] [342] [343] [344] [345] [346] [347] [348] [349] [350] • Vitreous opacity o Severe non-clearing, recurrent vitreous hemorrhage 
Further recommendation
Studies have shown that while stopping anti-coagulant medications decreases the risk of vitreous hemorrhage during vitrectomy, at the same time it increases mortality. Therefore, decision regarding maintenance or perioperative discontinuation of anticoagulation therapy should be made before vitrectomy by having appropriate consultations about patients' systemic conditions. [351] [352] [353] (EL: II)
Cataract surgery in diabetic patients
Patients should undergo thorough retinal examination prior to the surgery. [261] [262] [263] [354] [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] (EL: II)
Coexisting PDR should be treated with PRP preoperatively if media is clear. However, in eyes with poor visualization due to cataract, fundus examination should be performed as soon possible following cataract surgery. [261] [262] [263] [354] [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] (EL: I)
Patients with DME should receive intravitreal injection of steroid or anti-VEGF preoperatively to lower the risk of DME aggravation. [261] [262] [263] [354] [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] (EL: I)
Patients should undergo more frequent retinal examinations postoperatively due to their increased risk for progression of DR. [261] [262] [263] [354] [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] (EL: II)
OCT should be done postoperatively to monitor diabetic macular edema. [261] [262] [263] [354] [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] (EL: II)
Diabetic patients who are cataract surgery candidates should be well informed about the risk of DR progression and probable consequent decreased vision and the necessity of frequent eye examination postoperatively. [261] [262] [263] [354] [355] [356] [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] 
DISCUSSION
Considering the high prevalence of DM and the role of DR as a leading cause of visual impairment and blindness, clinical practice guidelines for DR was adapted for Iranian population at the Knowledge Management Unit, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran at the request of the Ministry of Health and Medical Education to promote the diagnostic and therapeutic services and enhance community access to evidence-based eye care. [10, 11, 18, 371] Different management aspects of DR including screening, risk factors, follow-up, diagnosis and treatment were taken into account in this guideline.
The retinal experts reached consensus for the majority of the CPGs' recommendations and approved them as the final recommendations. However, those with no agreement upon were discussed, reviewed and revised, and the final recommendations were composed as follows:
Recommendations for Screening, Risk Factors and Follow-up
Recommendation for vitamin D
This recommendation was primarily described as "Vitamin D level is recommended to be checked in diabetics and treatment is advised for vitamin D deficient patients to decrease the risk of developing DR". However, vitamin D administration is not completely in the field of ophthalmology and could result in adverse effects in some patients. Therefore, this recommendation was ultimately revised to "As vitamin D deficiency can be associated with progression of DR, consultation with a specialist (endocrinologist or gastroenterologist, or nephrologist) is warranted for diabetic patients with vitamin D deficiency and coexisting renal and gastrointestinal problems." in order to share the responsibility of correcting Vitamin D with other specialists; hence minimizing the adverse outcomes.
Recommendations for Diagnosis
Recommendation for precautions for fluorescein angiography
Considering the large number of patients in whom fluorescein angiography is recommended, this recommendation was reviewed and after taking patients safety and consultation costs into account was revised from "Relevant consultations are recommended prior to performing fluorescein angiography in patients with history of heart and vascular problems, drug allergy, and lung and kidney diseases" to "It is recommended that patients with known history of cardiovascular diseases, allergy, and lung or kidney disorders have appropriate consultation before undergoing fluorescein angiography".
Recommendation for different types of fluorescein angiography
This recommendation was primarily described as "Wide-field fluorescein angiography is superior for peripheral retinal lesions and could alter patient's classification and impact treatment and follow-up plans". However, with respect to the experts' opinion, clinical preferences, and costs, this recommendation was reviewed and the indications became clearer and the ultimate recommendation was changed to "Wide-field fluorescein angiography is superior in cases with peripheral retinal lesions as it could alter the classification of the DR and therapeutic and follow-up approaches. Availability of wide-field fluorescein angiography can be limited to the major ophthalmology centers".
Recommendation for other imaging modalities
With respect to the consensus reached and the viewpoints of the technical committee of the Ministry of Health and Medical Education, the recommendation for retinal imaging underwent major revision and the final version was composed.
The primary recommendation was as follows: "New imaging techniques for retinopathy include Heidelberg retina angiograph (HRA), optical coherence tomography (OCT), retinal thickness analyzer (RTA) and fundus autofluorescence (FAF). a. OCT in DR is recommended for the following scenarios: 1. Macular thickness measurements, follow-up or treatment of macular edema 2. To diagnose tractional macular thickening. b. HRA, as an angiographic tool has the following characteristics: 1. Providing digital images 2. High speed angiography 3. High resolution. c. FAF is employed for evaluating the functional RPE changes without need to inject any dye." It is recommended to use these imaging tools, for the above-mentioned purposes with exception of RTA that has no clinical application.
However, following experts' consensus and considering the professional suggestions of the mentioned committee to specify the clinical application of the recommendation, the recommended conditions for using OCT were revised. In addition, specific characteristics of the new fluorescein angiography techniques including high speed, high resolution, and saving images in digital format were described. The application of FAF was also defined more precisely and the final version was composed as follows:
"New imaging modalities for evaluation of DR include new angiographic, retinal thickness analysis (RTA) techniques, optical coherence tomography (OCT) and fundus autofluorescence (FAF).
• Due to the particular properties of OCT such as demonstrating different layers of retina, the use of OCT it is recommended to be used in the following conditions: o To determine the macular thickness in diabetic macular edema (before and after treatment) o To detect vitreoretinal traction or any membrane on the macula.
• Due to the particular properties of new fluorescein angiography techniques (SLO [Scanning Laser Ophthalmoscopy] Angiography) such as high-speed imaging, high resolution, possibility of digitally storing the images, and integrating the patients' data from different medical centers, it is suggested that these imaging modalities be available in the majority of public and private settings.
• FAF can investigate functional changes in retinal pigment epithelium (RPE) without the injection."
Recommendations for Treatment
Recommendations for treatment are the most important part in this clinical guideline, therefore the customization team revised them multiple times based on the experts' opinions.
Recommendation for indications of macular laser treatment
This recommendation was primarily written as follows: "Macular Laser treatment is recommended in the following scenarios: 1. Presence of CSME according to ETDRS study 2. One of the following conditions even in the absence of diagnostic criteria for CSME: o Macular edema progressing to central macula (leaking upper macular lesions, hard exudate approaching the central macula) o In patients incapable of regular follow-up every 3 months o Cataract surgery candidates (in patients with cataract who have leaking macular lesions in their fundus, laser treatment of macular edema is recommended before the cataract surgery) o Permanent vision loss in the fellow eye as a result of CSME o In PRP candidates, laser treatment of macula is recommended prior to or concurrent with PRP to prevent worsening of macular edema." This recommendation was revised to emphasize on intravitreal anti-VEGF injections as one of the principal treatments for macular edema as below:
"Macular laser photocoagulation should be considered in the following conditions:
• Presence of clinically significant macular edema (CSME) according to ETDRS.
(More recent studies recommend intravitreal injection of anti-VEGF in cases with center involving macular edema and visual acuity of less than 20/30 to 20/40; however, if the macular center is spared and visual acuity is higher than 20/30 to 20/40, macular laser photocoagulation can be applied.)
• Any of the following conditions even in the absence of CSME features: o Progression of macular edema towards the central parts of the macula o Patients who cannot be followed every 3 months o Cataract surgery candidates with leaking macular lesions may receive macular laser treatment preoperatively. o Permanent vision loss in the fellow eye due to CSME. o In order to prevent aggravation of macular edema, PRP candidates with coexisting diabetic macular edema (DME) should receive intravitreal anti-VEGF injection prior to undergoing laser treatment."
Recommendation for follow-up after macular laser photocoagulation
The primary recommendation of the customization team for follow-up after laser treatment of the macula was:
"After laser treatment for macular edema, follow-up is recommended every 2-4 months until stabilization of the condition. Subsequent laser retreatment will be planned based on visual acuity (better than 20/30) and no involvement of central fovea." According to the Ministry of Health and Medical Education Technical Committee, the reason of disagreement in the consensus process was re-evaluated. For this purpose and in order to make this recommendation more practical, a determinant VA for retreatment was extracted from two valid references; [215, 135] VA of "20/30" was replaced by "20/30 or 20/40" and the final recommendation was composed as:
"According to DRS and ETDRS, patients should be followed at 2-4 months intervals after macular laser treatment; decision for retreatment will be based on visual acuity (better than 20/30 or 20/40) and involvement of the central fovea thereafter."
Recommendation for new laser therapy techniques
Considering the high cost of the instrument equipped with minimal invasive subthreshold technique, the initial recommendation "Considering the availability, lower rate of retinal damage and the higher speed of laser procedure with the retinal laser platform by the minimal invasive subthreshold technique, it is recommended for ophthalmologists to use the above-mentioned retinal laser platform" was replaced by "Considering the lower risk of retinal damage with minimally invasive subthreshold technique, a limited number of laser machines equipped with these technologies are recommended to be available in ophthalmology centers".
In 
